Pattern Separation in Major Depressive Disorder

Part of paid clinical trials in New York, New York.

Sponsor
Jeffrey Miller
Study ID
NCT07139834
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Major Depressive Disorder (MDD)

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • SSRI (escitalopram or sertraline) — DRUG
    11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
  • Extended-Release Memantine — DRUG
    6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
  • Placebo — DRUG
    6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment

Study Details

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Key Dates

First listed
Aug 24, 2025
Start date
Jun 1, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: SSRI + Memantine
  • Placebo Comparator: SSRI + Placebo

Primary Outcome Measure

Pattern Separation Performance [ Time Frame: At baseline (week 0) and after completing the medication trial (week 11) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York State Psychiatric Institute (NYSPI)New YorkNew York10032
Jeffrey M Miller, MD
[email protected]
646-774-7613
Gabriella F Restifo-Bernstein, BA
[email protected]
646-774-8138
Jeffrey M Miller, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site
New York State Psychiatric Institute (NYSPI)· New York, NY

Related Studies